Influenza Virus Genomic Surveillance, Arizona, USA, 2023-2024

Rabia Maqsood,Matthew F. Smith,LaRinda A. Holland,Regan A. Sullins,Steven C. Holland, Michelle Tan, Gabrielle M. Hernandez Barrera, Alexis W. Thomas, Mario Islas,Joanna L. Kramer, Lora Nordstrom,Mary Mulrow,Michael White,Vel Murugan,Efrem Lim

medrxiv(2024)

引用 0|浏览2
暂无评分
摘要
We conducted genomic sequencing of 110 influenza A and 30 influenza B viruses from specimens collected between October 2023 and February 2024 in Arizona, USA. We identified mutations in the hemagglutinin (HA) antigenic sites. Real-time genomic surveillance is important to ensure influenza vaccine effectiveness. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported in part by Arizona State University, and the Centers for Disease Control and Prevention (CDC U01 IP001180). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by site reliance on Duke University (Pro00112115) and Arizona State University (STUDY00011967) Institutional Review Boards. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要